Jay Luly, Enanta Pharmaceuticals CEO

Enan­ta is look­ing for a part­ner on its Covid pill af­ter a PhII study dis­ap­points

A biotech com­pa­ny with am­bi­tions to com­pete with Pfiz­er’s block­buster Covid-19 pill an­nounced mixed re­sults from a study of its ex­per­i­men­tal an­tivi­ral ther­a­py and won’t car­ry for­ward with de­vel­op­ment of the drug on its own.

Enan­ta Phar­ma­ceu­ti­cals said Mon­day that its pill, EDP-235, met its pri­ma­ry end­points of safe­ty and tol­er­a­bil­i­ty in its Phase II tri­al, dubbed SPRINT, but yield­ed mixed re­sults on its ef­fec­tive­ness. It failed to clear the virus faster than a place­bo and failed to speed up re­cov­ery of 14 symp­toms of Covid, al­though the com­pa­ny em­pha­sized that the treat­ment ap­peared to im­prove a sub­set of symp­toms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.